Hematologic Malignancies: ASCO Meeting Highlights New Approaches To Treatment
Studies Test New Agents Offering Relief From Treatment-Related Side Effects
Oral UFT Equivalent To FULV In Stage II and III Colon Cancer
Adjuvant Chemo Improves Survival In Early Lung Cancer
Treat Cancer, But Protect Heart Anderson Cardiologists Warn
NCI-Approved Clinical Trials
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - In The Headlines: Private funding can’t replace federal funding—but it can help